



# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

February 9, 2018

National Stock Exchange of India Limited  
Exchange Plaza  
Bandra Kurla Complex  
Bandra (E) Mumbai 400 051

**Stock Symbol: JBCHEPHARM**

Dear Sir,

**Sub : Outcome of the Meeting of the Board of Directors - Unaudited Financial Results for the quarter ended on December 31, 2017.**

In compliance with Regulation 30(2) and Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with circular no. CIR/CFD/CMD/4/2015 dated September 09, 2015, enclosed please find unaudited financial results for the quarter ended on December 31, 2017 accompanied by limited review report. These financial results have been approved and taken on record by the Board of Directors at its meeting held today, which commenced at 12.00 noon and concluded at 1.50 p.m.

We request you to take the above on record.

Thanking you,

Yours faithfully,

for J. B. Chemicals & Pharmaceuticals Limited

M. C. Mehta  
Company Secretary and Vice President - Compliance

Encl: As above



# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2017

| Sl.No. | PART I - Particulars                                                          | Quarter ended |            |            | Nine Months |            | (Rs. in lakhs) |
|--------|-------------------------------------------------------------------------------|---------------|------------|------------|-------------|------------|----------------|
|        |                                                                               | 31/12/2017    | 30/09/2017 | 31/12/2016 | 31/12/2017  | 31/12/2016 | Year ended     |
|        |                                                                               | Unaudited     | Unaudited  | Unaudited  | Unaudited   | Unaudited  | Audited        |
| 1      | Revenue from Operations                                                       | 30,474.20     | 34,992.66  | 27,648.17  | 93,850.64   | 89,243.23  | 119,869.42     |
| 2      | Other Income                                                                  | 532.00        | 696.15     | 769.05     | 2,155.33    | 3,312.76   | 4,589.03       |
| 3      | Total Income (1+2)                                                            | 31,006.20     | 35,688.81  | 28,417.22  | 96,005.97   | 92,555.99  | 124,458.45     |
| 4      | Expenses                                                                      |               |            |            |             |            |                |
| a.     | Cost of materials consumed                                                    | 10,081.54     | 8,030.15   | 8,230.94   | 26,930.51   | 27,577.97  | 36,709.36      |
| b.     | Purchases of stock-in-trade                                                   | 2,279.03      | 3,861.00   | 2,320.23   | 8,576.95    | 6,766.95   | 9,624.47       |
| c.     | Changes in inventories of finished goods, work-in-progress and stock-in-trade | (1,676.13)    | 1,931.15   | (276.94)   | 120.78      | (1,142.02) | (1,805.26)     |
| d.     | Employee benefit expenses                                                     | 5,310.67      | 5,299.79   | 4,702.63   | 16,192.63   | 13,796.49  | 18,786.11      |
| e.     | Finance Costs                                                                 | 61.07         | 106.05     | 243.00     | 246.24      | 524.18     | 500.13         |
| f.     | Depreciation and amortization expense                                         | 1,425.00      | 1,432.71   | 1,135.96   | 4,290.55    | 3,385.96   | 4,626.42       |
| g.     | Other Expenses                                                                | 8,617.60      | 8,233.05   | 8,097.60   | 25,423.99   | 24,715.45  | 34,338.86      |
|        | Total Expenses (4)                                                            | 26,098.78     | 28,893.90  | 24,453.42  | 81,781.65   | 75,624.98  | 102,780.09     |
| 5      | Profit before Tax (3-4)                                                       | 4,907.42      | 6,794.91   | 3,963.80   | 14,224.32   | 16,931.01  | 21,678.36      |
| 6      | Tax expenses                                                                  | 1,522.36      | 1,622.49   | 387.70     | 3,630.11    | 3,849.46   | 4,381.90       |
| 7      | Net Profit/(Loss) after Tax (5-6)                                             | 3,385.06      | 5,172.42   | 3,576.10   | 10,594.21   | 13,081.55  | 17,296.46      |
| 8      | Other Comprehensive Income (net of Tax)                                       | (13.10)       | (13.08)    | (8.08)     | (93.79)     | (24.22)    | (270.43)       |
| 9      | Total Comprehensive Income after Tax (7+8)                                    | 3,371.96      | 5,159.34   | 3,568.02   | 10,500.42   | 13,057.33  | 17,026.03      |
| 10     | (i) Earning per share(EPS) (of Rs. 2/- each not annualised)                   |               |            |            |             |            |                |
|        | (1) Basic                                                                     | 4.03          | 6.16       | 4.22       | 12.62       | 15.42      | 20.39          |
|        | (2) Diluted                                                                   | 4.03          | 6.16       | 4.22       | 12.62       | 15.42      | 20.39          |

### Notes:

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 9, 2018.
- Post applicability of Goods and Service Tax (GST) with effect from July 1, 2017, the sales and services which are subjected to GST are disclosed net of GST. Accordingly, the sales and services for the quarter and nine months ended December 31, 2017 are not comparable with the previous corresponding periods as the figures for those periods were inclusive of excise duty.
- Provision for tax for the quarter ended December 31, 2017 is higher compare to the corresponding quarter ended December 31, 2016 as in the quarter ended December 31, 2016, Company was liable for tax on book profit under MAT provision of the Income Tax Act, 1961, which in the current year is not applicable.
- The auditors have carried out limited review of the financial results for the quarter ended on December 31, 2017 and their report does not contain any qualification.
- The Company has one reportable segment viz. Pharmaceuticals.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.

J.B.Mody  
Chairman & Managing Director

Place : Mumbai  
Date : 9/02/2018

Registered Office:  
Neelam Centre, B Wing, 4th Floor  
Hind Cycle Road, Worli  
Mumbai - 400 030

Corporate Office:  
Energy IT Park  
Unit A2, 3rd Floor, Unit A, 8th Floor  
Appa Saheb Marathe Marg, Prabhadevi  
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500  
+91 22 2431 5331 / 2431 5334  
@ info@jbcpl.com  
www.jbcpl.com  
CIN: L24390MH1976PLC019380

**Limited Review Report on Unaudited Standalone Financial Results for the Quarter and Nine month ended December 31, 2017 of J. B. Chemicals and Pharmaceuticals Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**To the Board of Directors of  
J. B. Chemicals and Pharmaceuticals Limited**

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results ('the Statement') of **J. B. Chemicals and Pharmaceuticals Limited** ('the Company'), for the quarter and Nine months period ended December 31, 2017 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016, which has been initialed by us for the purpose of identification.
2. This statement is the responsibility of the Company's Management and has been reviewed by the Audit Committee and approved by the Board of Directors, in their respective meetings held on February 9, 2018. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' ('the Standard'), issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

**Other Matter:**

4. The comparative figures for the quarter and Nine months period ended December 31, 2016 and the year ended March 31, 2017 prepared in accordance with applicable Indian Accounting Standards ('Ind AS') were reviewed / audited by the erstwhile auditors who had expressed unmodified limited review/ audit opinion on these financial results/ financial statements vide their reports dated February 10, 2017 and May 23, 2017 respectively.



Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Standalone Financial Results prepared in accordance with applicable Ind AS prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Damania & Varaiya**

Firm Registration No.: 102079W

Chartered Accountants

 

**CA Bharat Jain**

Partner

Membership No.: 100583

Place: Mumbai

Date: February 9, 2018



# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2017

(Rs. in lakhs)

| Sl.No. | PART I - Particulars                                                             | Quarter ended |            |            | Nine Months |            | Year ended |
|--------|----------------------------------------------------------------------------------|---------------|------------|------------|-------------|------------|------------|
|        |                                                                                  | 31/12/2017    | 30/09/2017 | 31/12/2016 | 31/12/2017  | 31/12/2016 | 31/03/2017 |
|        |                                                                                  | Unaudited     | Unaudited  | Unaudited  | Unaudited   | Unaudited  | Audited    |
| 1      | Revenue from Operations                                                          | 30,474.20     | 34,992.66  | 27,648.17  | 93,850.64   | 89,243.23  | 119,869.42 |
| 2      | Other Income                                                                     | 532.00        | 696.15     | 769.05     | 2,155.33    | 3,312.76   | 4,589.03   |
| 3      | Total Income (1+2)                                                               | 31,006.20     | 35,688.81  | 28,417.22  | 96,005.97   | 92,555.99  | 124,458.45 |
| 4      | Expenses                                                                         |               |            |            |             |            |            |
|        | a. Cost of materials consumed                                                    | 10,081.54     | 8,030.15   | 8,230.94   | 26,930.51   | 27,577.97  | 36,709.36  |
|        | b. Purchases of stock-in-trade                                                   | 2,279.03      | 3,861.00   | 2,320.23   | 8,576.95    | 6,766.95   | 9,624.47   |
|        | c. Changes in inventories of finished goods, work-in-progress and stock-in-trade | (1,676.13)    | 1,931.15   | (276.94)   | 120.78      | (1,142.02) | (1,805.26) |
|        | d. Employee benefit expenses                                                     | 5,310.67      | 5,299.79   | 4,702.63   | 16,192.63   | 13,796.49  | 18,786.11  |
|        | e. Finance Costs                                                                 | 61.07         | 106.05     | 243.00     | 246.24      | 524.18     | 500.13     |
|        | f. Depreciation and amortization expense                                         | 1,425.00      | 1,432.71   | 1,135.96   | 4,290.55    | 3,385.96   | 4,626.42   |
|        | g. Other Expenses                                                                | 8,617.60      | 8,233.05   | 8,097.60   | 25,423.99   | 24,715.45  | 34,338.86  |
|        | Total Expenses (4)                                                               | 26,098.78     | 28,893.90  | 24,453.42  | 81,781.65   | 75,624.98  | 102,780.09 |
| 5      | Profit before Tax (3-4)                                                          | 4,907.42      | 6,794.91   | 3,963.80   | 14,224.32   | 16,931.01  | 21,678.36  |
| 6      | Tax expenses                                                                     | 1,522.36      | 1,622.49   | 387.70     | 3,630.11    | 3,849.46   | 4,381.90   |
| 7      | Net Profit/(Loss) after Tax (5-6)                                                | 3,385.06      | 5,172.42   | 3,576.10   | 10,594.21   | 13,081.55  | 17,296.46  |
| 8      | Other Comprehensive Income ( net of Tax)                                         | (13.10)       | (13.08)    | (8.08)     | (93.79)     | (24.22)    | (270.43)   |
| 9      | Total Comprehensive Income after Tax (7+8)                                       | 3,371.96      | 5,159.34   | 3,568.02   | 10,500.42   | 13,057.33  | 17,026.03  |
| 10     | (i) Earning per share(EPS) (of Rs. 2/- each not annualised)                      |               |            |            |             |            |            |
|        | (1) Basic                                                                        | 4.03          | 6.16       | 4.22       | 12.62       | 15.42      | 20.39      |
|        | (2) Diluted                                                                      | 4.03          | 6.16       | 4.22       | 12.62       | 15.42      | 20.39      |

### Notes:

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 9, 2018.
- Post applicability of Goods and Service Tax (GST) with effect from July 1, 2017, the sales and services which are subjected to GST are disclosed net of GST. Accordingly, the sales and services for the quarter and nine months ended December 31, 2017 are not comparable with the previous corresponding periods as the figures for those periods were inclusive of excise duty.
- Provision for tax for the quarter ended December 31, 2017 is higher compare to the corresponding quarter ended December 31, 2016 as in the quarter ended December 31, 2016, Company was liable for tax on book profit under MAT provision of the Income Tax Act, 1961, which in the current year is not applicable.
- The auditors have carried out limited review of the financial results for the quarter ended on December 31, 2017 and their report does not contain any qualification.
- The Company has one reportable segment viz. Pharmaceuticals.
- The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.

J.B.Mody  
Chairman & Managing Director

Place : Mumbai  
Date : 9/02/2018



Registered Office:  
Neelam Centre, B Wing, 4th Floor  
Hind Cycle Road, Worli  
Mumbai - 400 030

Corporate Office:  
Cnergy IT Park  
Unit A2, 3rd Floor, Unit A, 8th Floor  
Appa Saheb Marathe Marg, Prabhadevi  
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500  
+91 22 2431 5331 / 2431 5334  
info@jbcpl.com  
www.jbcpl.com  
CIN: L24390MH1976PLC019380